News & Press
Wall Street Journal Article Excerpt – April 28, 2021
Mr. Breton, by that point, had moved on to helping ensure future production can run more smoothly. That is why at Easter, with most of France observing the holiday or under lockdown, he traveled by train to Dijon to visit a factory making ingredients for Moderna and other pharmaceutical companies.
The plant, owned by Luxembourg-based CordenPharma GmbH, has increased production several hundredfold over recent months and now employs five teams running nonstop.
Arriving on the sunny Sunday morning, Mr. Breton greeted workers like a general reviewing troops. “It’s thanks to women and men like you that we will win this fight,” he exhorted them.
Mr. Breton greeted workers like a general reviewing troops. “It’s thanks to women and men like you that we will win this fight,” he exhorted them.
Inside, CEO Michael Quirmbach explained his rising output and the limits he faces, including a need to send some ingredients to foreign plants—including in the U.S.—for purification. A €30 million investment, equivalent to $36.3 million, would let the plant handle the task and increase production, while another €30 million investment would allow the company to fill vials and finish packaging for more than 100 million extra vaccine doses annually at a plant in Italy, he said.
Mr. Breton told his chief of staff to note the amounts, which the EU could help fund. “This is something very important for us,” he said.